Neurologists at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting welcomed the introduction of the first US Food and Drug Administration-approved anti-amyloid antibody for early Alzheimer’s disease to also win Medicare coverage – Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab) – but also noted the thoughtful process their affiliated health care centers are undertaking to make sure the therapy gets to appropriate patients.
Key Takeaways
-
Treating early Alzheimer’s disease with anti-amyloid therapies, like Eisai/Biogen’s Leqembi, involves PET scans, MRI monitoring, genetic testing and infusion of the medicines – a complicated process...
The FDA converted Leqembi’s accelerated approval to a traditional approval on 6 July, and the Centers for Medicare and Medicaid Services (CMS) simultaneously announced that Medicare would cover the drug....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
